Remyelinating and neuroprotective treatments in multiple sclerosis

Stangel, Martin·2004·Expert Opinion on Investigational Drugs
DOI 10.1517/13543784.13.4.331

Cites (211)

Items 201–211 of 211

  1. Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: implications for remyelination
    Martin Stangel, d’ Espagnat Bernard · 2003 · Journal of Neuroimmunology
  2. Comparison of Intravenous Immunoglobulin Preparations on Microglial Function In Vitro: More Potent Immunomodulatory Capacity of an IgM/IgA-Enriched Preparation
    Refik Pul, Dan Nguyen, Ulrike Schmitz · 2002 · Clinical Neuropharmacology
  3. Sim FJ, Zhao C, Penderis J, Franklin RJM. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation.
    Syndee J. Givre · 2003 · Journal of Neuro-Ophthalmology
  4. Remyelination in the CNS of the hypothyroid rat
    Robin J.M. Franklin, Jennifer M. Gilson · 1996 · Neuroreport
  5. Palmitoylation of the p75 neurotrophin receptor has no effect on its interaction with TrkA or on TrkA-mediated down-regulation of cell adhesion molecules
    Jouni Vesa, Alex Kr�ttgen, José Miguel Cosgaya, E.M. Shooter · 2000 · Journal of Neuroscience Research
  6. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights substrates of disability
    Sperfeld · 1999 · Pure Amsterdam UMC
  7. Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
    2000 · Pure Amsterdam UMC
  8. Untitled work
    Melcangi · 1999 · 10.1002/(sici)1097-4695(19990915)40:4
  9. Untitled work
    2000 · 10.1002/1531-8249(200012)48:6
  10. Untitled work
    S Forss-Petter · 1997 · 10.1002/(sici)1097-4547(19971201)50:5
  11. Untitled work
    2000 · 10.1002/1097-4547(20000801)61:3